Mulmit

Aspira Women's Health Inc.Aspira Women's Health Inc.

AWHL OTC

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-319,216,000-7,913,000-12,780-0.37
2024-12-319,182,000-16,278,000-13,094-0.93
2023-12-319,154,000-18,852,000-16,990-1.81

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-06-16Strahley JohnChief Financial Officer75,000
2026-06-05SCHULER JACK W222,222
2026-06-05SCHULER JACK W300,000
2025-12-02Hundorfean Cynthia D238,085
2025-12-02Fraser John D314,811
2025-12-02Wood Jane Pine135,592
2025-12-02Parnell Winfred185,178
2025-12-02cohen Jeffrey k213,518
2025-12-02Beausang Ellen198,097
2025-09-17cohen Jeffrey k11,112
2025-09-17SCHULER JACK W1,111,111
2025-09-17SCHULER JACK W833,333

8-K events

FiledItems
2026-07-15Entry into a material agreement · Creation of a direct financial obligation · Financial statements and exhibits
2026-07-07Officer or director change · Financial statements and exhibits
2026-06-22Officer or director change
2026-06-17Submission of matters to a vote
2026-06-09Entry into a material agreement · Unregistered sales of equity securities · Financial statements and exhibits
2026-05-26Entry into a material agreement · Financial statements and exhibits
2026-04-30Officer or director change
2026-03-25Entry into a material agreement · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

In Vitro & In Vivo Diagnostic Substances — 같은 업종, 그리고 규모가 비슷한 기업In Vitro & In Vivo Diagnostic Substances — and other companies of a similar size

SEC가 같은 업종(In Vitro & In Vivo Diagnostic Substances)으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (In Vitro & In Vivo Diagnostic Substances) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.